New combo therapy shows promise for rare stomach cancer in early trial
NCT ID NCT07178340
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests a combination of chemotherapy drugs and an immunotherapy drug for a rare type of stomach cancer called hepatoid adenocarcinoma. The treatment is given before and after surgery to see if it can shrink the tumor and improve outcomes. The trial involves 30 participants with locally advanced, HER2-negative cancer who are healthy enough for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOID ADENOCARCINOMA OF STOMACH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.